Mesa Laboratories (NASDAQ:MLAB) Shares Cross Above Fifty Day Moving Average – Here’s What Happened

Mesa Laboratories, Inc. (NASDAQ:MLAB)’s share price crossed above its 50 day moving average during trading on Tuesday. The stock has a 50 day moving average of $128.45 and traded as high as $138.08. Mesa Laboratories shares last traded at $136.91, with a volume of 234,179 shares trading hands.

Trending Headlines about Mesa Laboratories

Here are the key news stories impacting Mesa Laboratories this week:

• Positive Sentiment: Jefferies raised its price target to $150 from $125 and maintained a Buy rating, implying about 9.6% upside from the cited share price. Analyst price target report
• Positive Sentiment: Fiscal Q2 adjusted EBITDA rose 21.1% to $17.3 million, operating income increased 77.6%, and net income grew 75.3%. Mesa also repaid $11.4 million of debt, lowering its net leverage ratio to 1.75. Q2 results and guidance
• Positive Sentiment: The company authorized a new share-repurchase program of up to $40 million, which may support demand for shares, though repurchases are discretionary. Fiscal 2027 adjusted EBITDA guidance of $66 million–$68 million also forecasts 5%–8% growth. Company announcement
• Neutral Sentiment: Revenue increased 2.6% to $62.3 million, slightly above consensus, while the $250 million–$255 million full-year revenue forecast broadly brackets the $254.5 million consensus estimate. Company announcement
• Neutral Sentiment: A short-interest report lists 0 shares sold short, so it does not indicate meaningful short-covering potential.
• Negative Sentiment: Reported diluted EPS of $0.75 missed the cited analyst consensus of $2.29. Biopharmaceutical Development revenue fell 8.2%, and Clinical Genomics revenue fell 8.8%; Mesa expects Clinical Genomics sales to decline further in the second half and into fiscal 2028. Q2 results and guidance

Wall Street Analysts Forecast Growth

Several research firms have recently commented on MLAB. Weiss Ratings raised shares of Mesa Laboratories from a “hold (c-)” rating to a “hold (c)” rating in a research report on Thursday, October 8th. Wall Street Zen upgraded shares of Mesa Laboratories from a “buy” rating to a “strong-buy” rating in a research report on Saturday, October 3rd. Jefferies Financial Group boosted their target price on shares of Mesa Laboratories from $125.00 to $150.00 and gave the company a “buy” rating in a research report on Tuesday. Finally, Wells Fargo & Company upped their target price on shares of Mesa Laboratories from $94.00 to $110.00 and gave the company an “equal weight” rating in a report on Friday, August 14th. One analyst has rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $130.00.

Mesa Laboratories Trading Up 7.1%

The stock has a fifty day moving average of $128.45 and a 200 day moving average of $105.41. The company has a market capitalization of $766.15 million, a P/E ratio of 120.10 and a beta of 1.08. The company has a debt-to-equity ratio of 0.73, a quick ratio of 1.32 and a current ratio of 1.79.

Mesa Laboratories (NASDAQ:MLAB) last released its quarterly earnings results on Monday, August 10th. The medical instruments supplier reported $2.68 earnings per share (EPS) for the quarter. Mesa Laboratories had a return on equity of 23.00% and a net margin of 2.65%. The business had revenue of $60.14 million during the quarter.

Mesa Laboratories Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 15th. Stockholders of record on Monday, November 30th will be paid a $0.16 dividend. The ex-dividend date of this dividend is Monday, November 30th. This represents a $0.64 annualized dividend and a dividend yield of 0.5%. Mesa Laboratories’s dividend payout ratio (DPR) is 56.14%.

Insider Activity

In related news, CEO Siddhartha Kadia acquired 7,093 shares of the stock in a transaction dated Thursday, August 13th. The shares were purchased at an average cost of $112.80 per share, with a total value of $800,090.40. Following the transaction, the chief executive officer directly owned 7,093 shares in the company, valued at approximately $800,090.40. This represents a ? increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director John Sullivan sold 7,093 shares of the business’s stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $112.80, for a total value of $800,090.40. Following the transaction, the director owned 17,834 shares of the company’s stock, valued at approximately $2,011,675.20. This trade represents a 28.46% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders own 2.80% of the company’s stock.

Institutional Trading of Mesa Laboratories

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Ranger Investment Management L.P. bought a new stake in shares of Mesa Laboratories during the 2nd quarter valued at $17,321,000. Diamond Hill Capital Management LLC Investment Advisor purchased a new position in shares of Mesa Laboratories during the 2nd quarter valued at $15,507,000. William Blair Investment Management LLC bought a new position in Mesa Laboratories in the 3rd quarter worth $16,934,000. Aberdeen Group plc bought a new position in Mesa Laboratories in the 3rd quarter worth $13,137,000. Finally, Wasatch Advisors LP increased its stake in Mesa Laboratories by 125.8% in the 2nd quarter. Wasatch Advisors LP now owns 115,668 shares of the medical instruments supplier’s stock worth $11,515,000 after buying an additional 64,435 shares in the last quarter. 90.60% of the stock is owned by hedge funds and other institutional investors.

Mesa Laboratories Company Profile

Mesa Laboratories, Inc. develops and manufactures instruments and consumable products used to monitor and control quality in life sciences and other regulated industries. Its offerings support activities such as sterilization and disinfection monitoring, laboratory testing, biopharmaceutical development, and equipment calibration. The company’s products include biological and chemical indicators, data loggers, calibration instruments, and tools used in clinical genomics and bioprocessing. Customers use these products to help verify processes, measure conditions, and meet quality requirements.